$CLYD · BEACON TOPCO, INC.
Beacon Topco, Inc. filed an 8-K reporting the completion of its acquisition of Barinthus Biotherapeutics plc via a court-sanctioned UK scheme of arrangement effective September 9, 2026. In connection with the transaction, the company launched a tender offer on September 15, 2026 to purchase up to $15 million of its common stock at $6.6609 per share. The company also adopted an amended and restated certificate of incorporation and amended and restated bylaws.
- Beacon Topco acquired Barinthus Biotherapeutics via court-sanctioned UK scheme of arrangement, effective September 9, 2026.
- The company launched a tender offer to purchase up to $15 million of its common stock at $6.6609 per share.
- Beacon Topco adopted an amended and restated certificate of incorporation and bylaws in connection with the transaction.
- The original merger agreement was dated September 29, 2025, and amended on February 22, 2026.
- Barinthus Bio is now a wholly-owned subsidiary of Beacon Topco following the transaction close.
Price data unavailable.
The deal closes a year-long M&A process and the concurrent tender offer provides a defined liquidity event for shareholders at a fixed price.
The transaction consolidates Barinthus Bio under Beacon Topco, a biotech roll-up structure, with the concurrent $15M tender offer providing partial liquidity to shareholders post-merger.
Forward-looking statements highlight risks around pipeline development, clinical trial outcomes, regulatory developments, funding and capital access, and the possibility that anticipated benefits of the restructuring may not materialize.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.